KIMCO REALTY CORP (KIM)       18.01  +0.5 (+2.86%)

18.01  +0.5 (+2.86%)

US49446R1095 - REIT - After market: 18.01 0 (0%)


Fundamental Rating

4

Overall KIM gets a fundamental rating of 4 out of 10. We evaluated KIM against 210 industry peers in the Equity Real Estate Investment Trusts (REITs) industry. KIM scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, KIM is valued expensive at the moment.




Profitability

Profitability Rating

1

KIM has a Piotroski-F score of 6.00. This indicates an average health and profitability for KIM.
KIM's Return On Assets of 0.55% is worse than the rest of the industry. The industry average Return On Assets is 3.34%. 94% of the industry peers have a better Return On Assets.

KIM's Return On Equity of 1.04% is worse than the rest of the industry. The industry average Return On Equity is 8.17%. 95% of the industry peers have a better Return On Equity.
KIM has a Profit Margin of 5.71%. This is below the industry average of 27.83%. 92% of the industry peers outperform KIM.
VS Industry

ROA (0.55%) VS Industry: 6% outperformed.

0.03
26.09

ROE (1.04%) VS Industry: 5% outperformed.

0.08
135.39

Profit Margin (5.71%) VS Industry: 8% outperformed.

0.08
881.04

Valuation

Valuation Rating

3

KIM's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
When comparing the current price to the book value of KIM, we can conclude it is valued correctly. It is trading at 1.17 times its book value.
Compared to an average industry price book ratio of 1.09, KIM is valued in line with its industry peers.
When comparing the Enterprise Value to EBITDA ratio of KIM to the average industry ratio of 15.65, KIM is valued in line with its industry peers.

With a Price/Earnings Ratio of 29.05, KIM can be considered very expensive at the moment.
KIM's Price/Earning Ratio is slightly more expensive than the industry average, which is at 21.78.
With a Forward Price/Earnings Ratio of 26.00, KIM is valued very expensively.
VS Industry

Price/Earnings (29.05) VS Industry: 35% outperformed.

510.11
0.67

Price/Book (1.17) VS Industry: 47% outperformed.

46.45
0.08

Enterprise Value/ EBITDA (16.56) VS Industry: 42% outperformed.

128.53
2.05

Growth

Growth Rating

4

The Earnings Per Share is expected to grow by 12.85% on average over the next 5 years. This is quite good.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The Revenue has been growing slightly by 4.91% in the past year.
Measured over the past 5 years, KIM shows a small growth in Revenue. The Revenue has been growing by 7.55% on average per year.

The Revenue is expected to grow by 1.93% on average over the next 5 years.
The earnings per share for KIM have decreased strongly by -61.25% in the last year.
Measured over the past 5 years, KIM shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -28.93% on average per year.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-28.93% -41.58% -61.25% 66.28% 30.82% 23.13% 12.85%
Revenue7.55% 14.24% 4.91% 2.74% 3.12% 3.23% 1.93%

Health

Health Rating

6

The Current Ratio of KIM is much better than the industry average of 0.74.
When comparing the Quick Ratio to an average industry Quick Ratio of 0.66, KIM is better placed than the average industry peer to meet its short term obligations.
The Debt to Equity ratio of KIM is way better than the industry averages.
When comparing the Altman-Z score to an average industry score of 0.73, KIM is in better financial health than the average industry peer.

KIM has a Current Ratio of 1.39. This is a normal value and indicates that KIM is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.39 indicates that KIM should not have too much problems paying its short term obligations.
KIM has a Piotroski-F score of 6.00. This indicates an average health and profitability for KIM.
KIM has an Altman-Z score of 0.98. This is a bad value and indicates that KIM is not financially healthy and even has some risk of bankruptcy.
VS Industry

Debt/Equity (0.75) VS Industry: 70% outperformed.

21.53
0.00

Quick Ratio (1.39) VS Industry: 71% outperformed.

0.00
90.22

Current Ratio (1.39) VS Industry: 70% outperformed.

0.00
90.22

Altman-Z (0.98) VS Industry: 63% outperformed.

-0.94
37.03

Dividend

Dividend Rating

5

KIM has a Yearly Dividend Yield of 4.31%, which is a nice return.
KIM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.55.
KIM has been paying a dividend for at least 10 years, so it has a reliable track record.

Compared to an average industry Dividend Yield of 4.94, KIM is paying slightly less dividend.
The dividend of KIM decreases each year by -15.74%.
KIM pays out 552.61% of its income as dividend. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (4.31%) VS Industry: 35% outperformed.

0.27
13.72

KIMCO REALTY CORP18.01

NYSE:KIM (3/24/2023, 7:00:00 PM)+0.5 (+2.86%)

After market: 18.01 0 (0%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupReal Estate
GICS IndustryEquity Real Estate Investment Trusts (REITs)
Earnings (Last)02-09 2023-02-09/bmo
Earnings (Next)04-26 2023-04-26/bmo
Inst Owners95.58%
Inst Owner Change1.92%
Ins Owners2.2%
Ins Owner Change6.23%
Market Cap11.14B
Analysts74.81
Price Target24.27 (34.76%)
Dividend
Industry RankSector Rank
Dividend Yield 4.31%
Dividend Growth(5Y)-15.74%
DP552.61%
Div Incr Years2
Div Non Decr Years2
Ex-Date03-08 2023-03-08 (0.23)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)38.69%
Min EPS beat(2)-51.63%
Max EPS beat(2)129.01%
EPS beat(4)2
Avg EPS beat(4)-3.55%
Min EPS beat(4)-239.95%
Max EPS beat(4)148.36%
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)2.02%
Max Revenue beat(2)2.55%
Revenue beat(4)4
Avg Revenue beat(4)1.94%
Min Revenue beat(4)1.43%
Max Revenue beat(4)2.55%
PT rev (1m)-0.49%
PT rev (3m)-0.27%
EPS NQ rev (1m)2.92%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.01%
EPS NY rev (3m)-2.01%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)0.84%
Revenue NY rev (1m)0.86%
Revenue NY rev (3m)0.86%
Valuation
Industry RankSector Rank
PE 29.05
Fwd PE 26
P/S 6.45
P/FCF 30.39
P/OCF 12.94
P/B 1.17
P/tB 1.17
EV/EBITDA 16.56
EPS(TTM)0.62
EY3.44%
EPS(NY)0.69
Fwd EY3.85%
FCF(TTM)0.59
FCFY3.29%
OCF(TTM)1.39
OCFY7.73%
SpS2.79
BVpS15.38
TBVpS15.38
PEG (NY)0.44
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.55%
ROE 1.04%
ROIC 2.58%
ROICexc 2.61%
ROICexgc 2.64%
OM 33.12%
PM 5.71%
GM 69.27%
ROICexgc(3y)2.34%
ROICexcg growth 3Y-8.36%
ROICexcg growth 5Y-1.9%
ROICexc(3y)2.32%
ROICexc growth 3Y-8.2%
ROICexc growth 5Y-1.8%
OM growth 3Y-4.96%
OM growth 5Y-0.35%
PM growth 3Y-41.91%
PM growth 5Y-28.64%
GM growth 3Y-0.78%
GM growth 5Y-1.34%
F-Score6
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF 19.52
Debt/EBITDA 6.64
Cap/Depr 97.92%
Profit Quality 371.93%
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z 0.98
F-Score6
WACC6.65%
ROIC/WACC0.4
Cap/Depr(3y)128.28%
Cap/Depr(5y)143.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-61.25%
EPS 3Y-41.58%
EPS 5Y-28.93%
EPS growth Q2Q192.31%
EPS Next Y66.28%
EPS Next 2Y30.82%
EPS Next 3Y23.13%
EPS Next 5Y12.85%
Revenue growth 1Y4.91%
Revenue growth 3Y14.24%
Revenue growth 5Y7.55%
Revenue growth Q2Q3.57%
Revenue Next Year2.74%
Revenue Next 2Y3.12%
Revenue Next 3Y3.23%
Revenue Next 5Y1.93%
EBIT growth 1Y5.63%
EBIT growth 3Y8.57%
EBIT growth 5Y7.17%
EBIT Next Year120.5%
EBIT Next 3Y30.68%
EBIT Next 5Y18.73%
FCF growth 1Y322.54%
FCF growth 3Y38.5%
FCF growth 5Y34.5%
OCF growth 1Y39.14%
OCF growth 3Y13.85%
OCF growth 5Y6.99%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA